Novosteo

Novosteo is a biotechnology startup founded in 2017 with a mission to revolutionize bone recovery and health. The company's innovative solutions focus on accelerating healing with precision-targeted treatments. Utilizing a unique chemistry method for bone targeting and discovering new biologics, Novosteo aims to address issues related to patients' morbidity, mortality, and loss of mobility and productivity due to bone fractures, bone metastasis, and infections. The scientific co-founders, Stewart Low and Philip Low from Purdue University, have spearheaded the development of medications that speed up bone regeneration by delivering anabolic agents specifically to fracture surfaces. In January 2021, Novosteo secured a significant $5.50M Series A investment from prominent investors including Elevate Ventures, Kairos Ventures, BioCrossroads, and the Purdue Research Foundation. This funding injection not only validates the potential of Novosteo's groundbreaking approach but also provides the necessary resources to drive further research and development initiatives. As Novosteo continues to make strides in the biotechnology, healthcare, and pharmaceutical industries, its innovative solutions hold promise for transforming the treatment of bone injuries and diseases, ultimately improving patient outcomes and quality of life.